Nama Insights

Mineralys Therapeutics (MLYS)

Healthcare · Biotechnology · NASDAQ

Mineralys Therapeutics (MLYS) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.25B and a free-cash-flow yield of -14.9%. Nama's AI scorecard rates it Sell, 2.7 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 2.7/10
Clearly negative, short of the bottom band. As of Nov 20, 2026.
Momentum
Trailing · -49.6% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-71.3%
How far the last close sits under the highest price of the past five years.
Market cap$1.25B
Trailing P/E—
Price / book2.5
Price / sales—
FCF yield-14.9%
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.8
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

MLYS earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate -$0.67). Beat the EPS estimate in 1 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 4, 2026 -$0.64 -$0.55 -16.4% $0
Q2 2026 Aug 11, 2026 -$2.85 -$0.53 -437.7% $0
Q1 2026 May 6, 2026 -$0.47 -$0.44 -6.8% $0
Q4 2025 Mar 12, 2026 -$0.40 -$0.52 +23.1% $0

MLYS analyst price target

Median target $52.00 from 9 analysts, ranging $19.00 – $56.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live MLYS data on Nama Insights →

MLYS FAQ

Is MLYS a buy?
Nama's AI scorecard currently rates Mineralys Therapeutics Sell (2.7 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MLYS report earnings?
Mineralys Therapeutics's next scheduled report is on Feb 11, 2027. Analysts expect EPS of -$0.67.
What is the MLYS price target?
The median analyst price target from 9 analysts is $52.00, with a range of $19.00 – $56.00.
Is MLYS Shariah compliant?
Nama's AAOIFI-style screen reads Mineralys Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.